Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Paroxysmal nocturnal haemoglobinuria (PNH) Clinical criteria: Treatment Phase: Initial treatment (new patient) Patient must not have received prior treatment with this drug for this condition, AND Patient must have PNH granulocyte clone size equal to or greater than 10% within the last 3 months, AND Patient must have experienced an inadequate response/intolerance to either: (i) Complement 5 (C5) inhibitor, (ii) pegcetacoplan, AND Patient must have received treatment with at least one complement inhibitor for at least 3 months before initiating treatment with this drug unless intolerance of severity necessitating permanent treatment withdrawal had occurred, AND The treatment must be the sole PBS-subsidised therapy for this condition. Treatment criteria: Must be treated by a haematologist; OR Must be treated by a non-specialist medical physician who has consulted a haematologist on the patient's drug treatment details. Population criteria: Patient must be at least 18 years of age. The authority application must be made via the Online PBS Authorities System, or in writing via HPOS form upload or mail and must include: (1) details of the proposed prescription(s); and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). At the time of the authority application, details (result and date of result) of the following monitoring requirements must be provided: (i) Haemoglobin (g/L) (ii) Platelets (x109/L) (iii) White Cell Count (x109/L) (iv) Reticulocytes (x109/L) (v) Neutrophils (x109/L) (vi) Granulocyte clone size (%) (vii) Lactate Dehydrogenase (LDH) (viii) the upper limit of normal (ULN) for LDH as quoted by the reporting laboratory (ix) the LDH:ULN ratio (in figures, rounded to one decimal place)
“Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway while leaving the direct signalling from the lectin and classical pathways intact.”
“The half-life (t1/2) of iptacopan at steady state is approximately 25 hours after administration of FABHALTA 200 mg twice daily.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Here is a plain-language explainer for a family member or guardian of a patient prescribed iptacopan.
---
Understanding Iptacopan: A Guide for Family and Guardians
This guide explains what iptacopan is, how it works, and what you need to know to support your family member or the person in your care who has been prescribed it. It is based on official medical information but is written in everyday language.
What is iptacopan?
Iptacopan is a prescription medicine used to treat serious conditions where the body's immune system is overactive and attacks its own cells. The most common condition it treats is Paroxysmal Nocturnal Haemoglobinuria (PNH) . It may also be used for a kidney condition called C3 Glomerulopathy (C3G) .
In PNH, a part of the immune system called the "complement system" is overactive and destroys red blood cells, which can lead to anaemia, blood clots, and other serious problems. Iptacopan helps control this overactive immune response.
How Does It Work?
Think of the complement system as a set of dominoes that, when tipped over, cause inflammation and cell damage. Iptacopan works like a finger placed on one specific domino (called Factor B), stopping the chain reaction from starting.
It's a "proximal" inhibitor, meaning it acts very early in the process. It specifically targets one of the three ways the complement system can be activated (the "alternative pathway"), while leaving the other two pathways (the "classical" and "lectin" pathways) free to do their normal job of fighting infections.
How is it Taken?
- Your family member will take iptacopan twice a day, by mouth, with or without food. - The typical dose is 200 mg twice a day (morning and evening) . - The medication has a half-life of about 25 hours, which means it stays in the body for a good amount of time. Taking it consistently every day is very important to keep the "domino chain reaction" under control. - If a dose is missed, it should be taken as soon as remembered. If it's almost time for the next dose, skip the missed one and continue with the regular schedule. Do not double up on doses.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Metabolism of iptacopan includes N-dealkylation, O-deethylation, oxidation, and dehydrogenation, mostly driven by CYP2C8 (98%) with a small contribution from CYP2D6 (2%).”
Important Safety Information: What to Watch For
The most critical thing to know about iptacopan is that it affects the immune system and increases the risk of certain infections. You play a vital role in helping your family member stay safe.
⚠️ IMPORTANT: Risk of Serious Infection
Because iptacopan blocks a part of the immune system, it can make it harder for the body to fight off certain bacteria, especially those with a capsule (like a hard shell). The most serious risk is for infections from:
- Neisseria meningitidis (can cause meningitis) - Streptococcus pneumoniae (can cause pneumonia) - Haemophilus influenzae type B (can cause pneumonia, meningitis, and other infections)
Your Responsibilities: Vaccination is Mandatory
- Before starting iptacopan, your family member must be up-to-date on vaccinations against these bacteria. This is a strict requirement to protect them. - If they are not vaccinated, the doctor will only prescribe iptacopan if the risk of delaying treatment is greater than the risk of getting a